in a Biodel article.

"Of course, Biodel isn't the only company working on a better diabetes mousetrap. All of the existing insulin analog manufacturers are looking to extend their franchises with new products, and other biopharmas like Halozyme (HALO) and MannKind (MNKD) are working on their own insulins (including MannKind's inhaled form). If nothing else, MannKind is an abject lesson in the ups and downs of trying to bring a new mousetrap to the diabetes/insulin market."

http://seekingalpha.com/article/493651-biodel-back-at-square-one-not-zero